Aardvark Therapeutics, Inc. Common Stock

NASDAQ:AARD

Biotechnology

Healthcare
$3.95 +2.36%

+$0.09 today

Market cap
$86.45M
Beta
4.47
P/E (TTM)
-1.2
EPS (TTM)
-$3.20
52W Low $3.35High $17.94

Volume 1.32M

Average 0.18M

Returns on capital

Aardvark Therapeutics, Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-54.0%

avg 13.2%

ROIC

-58.6%

avg -59.9%

ROA

-49.1%

avg -56.3%

Analysis

ROA is currently the strongest return metric at -49.1% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Tien-Li Lee

CEO, Secretary & ChairmanUSD 973.66K51203.85K0.93%

Manasi Sinha Jaiman

Chief Medical OfficerUSD 693.04K45——

Nelson Sun

CFO & COOUSD 603.3K4935.48K0.16%

Bryan Jones

Chief Executive Officer of ArdiaUSD 467.44K621.25K<0.01%

Zhenhuan Zheng

Chief Research Officer————

Timothy J. Kieffer

Chief Scientific Officer—59——

Justin T. Stege

VP and Head of Project Management & Strategy————

Derrick C. Li

Chief Business Officer————

Ron Lewis

Vice President & Head of CMC————

Danny Villeneuve

Chief Commercial Officer————

Dvorit Samid

Executive Vice President of Medical Affairs————

Christian Zapf

General Counsel————

Compensation is shown in the reported currency; data updated Oct 3, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$144,595.00

Sells

2

$394,957.45

Net Transaction Value

−$250,362.45

Net selling

Most Active

Sun Nelson

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 11, 26

Sun Nelson

Direct

Sell$321.2K
Sep 10, 26

Sun Nelson

Direct

Sell$73.8K
Dec 11, 25

Sun Nelson

Direct

Buy$43.2K
Dec 11, 25

Lee Tien-Li

Direct

Buy$101.4K

Summary

Insiders reported 2 buys worth $144,595.00 and 2 sells worth $394,957.45 over the last 12 months. That adds up to net selling of $250,362.45. Sun Nelson was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Aardvark Therapeutics, Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AARD's management, answered from reported figures.

Who manages AARD?

Aardvark Therapeutics, Inc. Common Stock (AARD) lists 12 active executives. The top listed executive is Bryan Jones, Chief Executive Officer of Ardia.

Are AARD insiders buying or selling?

Recent insider activity shows net buying of $34.76M.